Search results for " progression"

showing 10 items of 1092 documents

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

2002

The feasibility of nonmyeloablative stem cell transplantation (NST) was evaluated in 22 adults with high-risk ALL. 16/22 patients had advanced disease and 11/22 had Ph+ ALL. Eleven patients received NST as first stem cell transplantation (SCT). Eleven patients had relapses after allogeneic or autologous SCT and underwent a salvage NST. 18/22 patients (82%) engrafted after NST. 13/16 patients (81%) with active disease reached complete remission (CR). 11 of 13 patients developed GVHD. After first NST 10/11 patients (91%) engrafted. Six of seven patients with active disease reached CR. Three of five relapsing patients reached subsequent CR after donor lymphocyte infusions, termination of immun…

AdultMaleRiskMelphalanCancer Researchmedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentSalvage therapyGraft vs Leukemia EffectPilot ProjectsAcute lymphocytic leukemiamedicineHumansPhiladelphia ChromosomeSurvival rateSalvage TherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationImmunosuppressionHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryFludarabineSurvival RateTransplantationsurgical procedures operativeOncologyDisease ProgressionFeasibility StudiesFemalebusinessmedicine.drugLeukemia
researchProduct

Efficacy and Tolerability of Biweekly Bevacizumab, Irinotecan, Folinic Acid and Fluorouracil Intravenous Bolus (BIFF Regimen) in Patients With Metast…

2011

Abstract Background We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC). Here, we report on the safety and activity of BIFF (bevacizumab plus IRIFAFU) regimen in 94 mCRC patients. Patients and Methods Bevacizumab 5 mg/kg (1 hour), and irinotecan 180 mg/m 2 (1hour) were given intravenously on day 1, 6S-folinic acid 250 mg/m 2 (2 hours), and fluorouracil 850 mg/m 2 (bolus) were given intravenously on day 2 every 2 weeks for a median of 9 cycles per patient (range, 1-12), and maintenance bevacizumab alone was delivered in 16 cases. Results Grade ≥ 3 hematologic toxicities were neutropenia (50%) …

AdultMaleRiskOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyBevacizumabLeucovorinAngiogenesis InhibitorsAntibodies Monoclonal HumanizedIrinotecanFolinic acidBolus (medicine)Internal medicineBiomarkers TumorConfidence IntervalsmedicineHumansInfusions IntravenousAgedbusiness.industryGastroenterologyAntibodies MonoclonalMiddle AgedMETASTATIC COLORECTAL CANCER BEVACIZUMABmedicine.diseaseAntineoplastic Agents PhytogenicSurvival AnalysisBevacizumabIrinotecanRegimenItalyOncologyTolerabilityFluorouracilVitamin B ComplexDisease ProgressionCamptothecinFemaleFluorouracilColorectal NeoplasmsbusinessFebrile neutropeniamedicine.drugClinical Colorectal Cancer
researchProduct

The Italian Multiple Sclerosis Database Network (MSDN): The risk of worsening according to IFNβ exposure in multiple sclerosis

2006

We evaluated the risk of worsening according to the length of exposure to interferon beta (IFNβ)ina large cohort of 2090 multiple sclerosis patients collected by the Italian MS Database Network. Overall 44-140 patient-visits with a follow-up of 22-143 patient-years were evaluated. Forty-one per cent of patients were exposed to IFNβ for up to 2 years, 39% for 2- 4 years and 20% for more than 4 years. A Cox regression model was used to analyse two clinical outcomes: disability progression and worsening of relapse rate. The technique of propensity score was applied to reduce bias in the comparison of non-randomized groups. The risks of disability progression (HR=0.23; 95% CI: 0.17 - 0.30) and …

AdultMaleTime Factorscomputer.software_genreCentral nervous system diseaseCohort Studies03 medical and health sciencesDisability Evaluation0302 clinical medicineAdjuvants ImmunologicmedicineHumansImmunologic Factors030212 general & internal medicineRisk factorMULTIPLE SCLEROSISDemographyProportional Hazards ModelsRISKAnalysis of VarianceDatabasebusiness.industryProportional hazards modelMultiple sclerosisInterferon-betaIFNP; Long term effectiveness; Multiple sclerosis; Observational studies;Middle Agedmedicine.diseaseTreatment OutcomeNeurologyDatabases as TopicItalyPropensity score matchingDisease ProgressionRegression AnalysisObservational studyFemaleNeurology (clinical)Analysis of variancebusinesscomputer030217 neurology & neurosurgeryCohort study
researchProduct

Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database

2019

ObjectivesA few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response.MethodsWe applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP. Clinical characteristics and treatment response were reviewed for each patient. The Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP.ResultsAt the time of inclusion, 376 (82%) patients had a diagnosis of typical CIDP while 84 …

AdultMaleTreatment responselewis-sumner syndromeAdolescentDatabases FactualDisease durationchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; Surgery; Neurology (clinical); Psychiatry and Mental HealthKaplan-Meier EstimateCIDPcomputer.software_genreDisease courseYoung Adultlewis–sumner syndrome03 medical and health sciences0302 clinical medicineHumansMedicineIn patientChildAgedRetrospective StudiesAged 80 and overchronic inflammatory demyelinating polyradiculoneuropathyRetrospective reviewdistal acquired demyelinating symmetric neuropathyDatabasebusiness.industryPolyradiculoneuropathyMiddle Agedchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndromemedicine.diseasePsychiatry and Mental healthchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; surgery; neurology ; psychiatry and mental healthItalyPolyradiculoneuropathy Chronic Inflammatory Demyelinatingdiagnostic criteriaDisease ProgressionFemaleSettore MED/26 - NeurologiaSurgeryProgression rateNeurology (clinical)CIDP; chronic inflammatory demyelinating polyradiculoneuropathy; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis–sumner syndromebusinesscomputer030217 neurology & neurosurgeryJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

2007

Objective: We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. Methods: A total of 45 heavily pretreated metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF during the treatment with cetuximab plus weekly irinotecan. VEGF circulating levels were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. Results: Basal VEGF median levels were s…

AdultMaleVascular Endothelial Growth Factor AOncologymedicine.medical_specialtyAngiogenesisColorectal cancerCetuximabAntibodies Monoclonal HumanizedIrinotecanangiogenesiscetuximabcolorectal canceririnotecansurvivalvascular endothelial growth factorBasal (phylogenetics)chemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorGeneticsmedicineHumansProspective StudiesProspective cohort studyAgedPharmacologyCetuximabbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateClinical trialVascular endothelial growth factorIrinotecanTreatment OutcomechemistryDisease ProgressionMolecular MedicineCamptothecinFemaleColorectal Neoplasmsbusinessmedicine.drugPharmacogenomics
researchProduct

Dysregulated Survivin Expression in Nasal Polyps of Individuals with Aspirin Exacerbated Respiratory Disease

2012

Background A derailed balance of cell proliferation and apoptosis is presumed to result in cell hyperplasia as a typical feature of nasal polyps. Survivin, a protein of the inhibitors of the apoptosis family is proposed to promote polyp formation. However, studies concerning survivin expression in chronic rhinosinusitis (CRS) with nasal polyps are rare and the specificity of the survivin expression in nasal polyps from individuals with aspirin-exacerbated respiratory disease (AERD) has not been investigated. Methods Immunohistochemical survivin expression analysis was performed. Samples were taken from the ethmoid sinus of individuals with CRS with nasal polyps with and without AERD during …

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtySurvivinApoptosisInhibitor of Apoptosis ProteinsDrug HypersensitivityYoung AdultNasal PolypsEthmoid SinusWestern blotSurvivinotorhinolaryngologic diseasesmedicineHumansImmunology and AllergyNasal polypsSinusitisneoplasmsCells CulturedRhinitisAspirinmedicine.diagnostic_testbusiness.industryRespiratory diseaseGeneral MedicineMiddle AgedHyperplasiamedicine.diseasePathophysiologyOtorhinolaryngologyApoptosisChronic DiseaseDisease ProgressionImmunohistochemistryFemalebusinessAmerican Journal of Rhinology & Allergy
researchProduct

Immunohistochemical analysis of cellular adhesion molecules (ICAM-1, VCAM-1) and VEGF in fibrovascular membranes of patients with proliferative diabe…

2009

Abstract Purpose Diabetic fibrovascular membranes are the main pathological changes of proliferative diabetic retinopathy that can cause serious complications leading to blindness. Since the mechanism of fibrovascular membrane development is still unknown, the aim of our study was to identify potential biomarkers for this pathology. To this end, we analyzed the simultaneous expression of ICAM-1, VCAM-1 and VEGF within tissues of diabetic fibrovascular membranes. Patients and methods Fibrovascular membranes were taken from nine diabetic patients with proliferative diabetic retinopathy. The fibrovascular membrane specimens were analyzed by immunohistochemistry to determine ICAM-1, VCAM-1 and …

AdultMaleVascular Endothelial Growth Factor AProliferative vitreoretinopathyPathologymedicine.medical_specialtyAgingBiopsyVascular Cell Adhesion Molecule-1Cataract Extractionchemistry.chemical_compoundYoung AdultReference ValuesDiabetes mellitusmedicineHumansVCAM-1AgedDiabetic RetinopathyCell adhesion moleculebusiness.industryRetinal VesselsGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseIntercellular Adhesion Molecule-1Immunohistochemistryeye diseasesVascular endothelial growth factor AchemistryImmunologyDisease ProgressionImmunohistochemistryFemalesense organsbusinessCell Adhesion MoleculesConjunctivaRetinopathyPathologie-biologie
researchProduct

Gray matter integrity predicts white matter network reorganization in multiple sclerosis

2019

Abstract Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease leading to gray matter atrophy and brain network reconfiguration as a response to increasing tissue damage. We evaluated whether white matter network reconfiguration appears subsequently to gray matter damage, or whether the gray matter degenerates following alterations in white matter networks. MRI data from 83 patients with clinically isolated syndrome and early relapsing–remitting MS were acquired at two time points with a follow‐up after 1 year. White matter network integrity was assessed based on probabilistic tractography performed on diffusion‐weighted data using graph theoretical analyses. We ev…

AdultMalegraph theory610 MedizinneuropsychologytractographyBiologyNeuropsychological Testsmultiple sclerosisGray (unit)050105 experimental psychologyWhite matter03 medical and health sciences0302 clinical medicineAtrophyMultiple Sclerosis Relapsing-Remittingatrophy610 Medical sciencesmedicineHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingstructural connectivityGray Matternetwork analysisResearch ArticlesTemporal cortexCerebral CortexClinically isolated syndromeRadiological and Ultrasound TechnologyMultiple sclerosisPutamen05 social sciencesMiddle Agedmedicine.diseaseWhite Mattermedicine.anatomical_structureDiffusion Tensor ImagingNeurologyDisease ProgressionFemaleNeurology (clinical)AnatomyNerve NetNeuroscience030217 neurology & neurosurgeryTractographyResearch ArticleFollow-Up StudiesHuman Brain Mapping
researchProduct

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis

2019

: Background: The role of the neutrophil-to-lymphocyte ratio (NLR) of peripheral blood has been investigated in relation to several autoimmune diseases. Limited studies have addressed the significance of the NLR in terms of being a marker of disease activity in multiple sclerosis (MS). Methods: This is a retrospective study in relapsing&ndash

AdultMalelymphocytesmedicine.medical_specialtyAdolescentlymphocyteLogistic regressionmultiple sclerosisArticleNLR; disease activity; lymphocytes; multiple sclerosis; neutrophilsNLRCohort StudiesDisease activityLeukocyte CountYoung AdultMultiple Sclerosis Relapsing-RemittingneutrophilsInternal medicinemedicineHumansNeutrophil to lymphocyte ratiolcsh:QH301-705.5Retrospective StudiesGenetic associationbusiness.industryMultiple sclerosisfungineutrophilRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseRelapsing remittinglcsh:Biology (General)multiple sclerosiCohortDisease ProgressionFemalebusinessdisease activityBiomarkers
researchProduct

The Candy Smell Test in Clinical Routine

2011

Background The “Candy Smell Test” (CST) has been introduced as a new testing method for the evaluation of the human sense of smell. In contrast to other established orthonasal smell tests, the CST addresses the retronasal application of odors, typical for food aroma effects during mastication and swallowing. The aim of this study was to evaluate the CST in a clinical setting in patients with olfactory dysfunction and normal controls against the Sniffin’ Sticks test. Furthermore, cutoff points for normal and pathological results in the CST should be determined. Methods The olfactory performance of 96 patients presenting with olfactory disorders and 71 healthy controls was evaluated with the …

AdultMalemedicine.medical_specialtyAdolescentMEDLINEAudiologyCandyOlfaction DisordersReference ValuesParanasal SinusesHumansImmunology and AllergyMedicineChildAgedDiagnostic Tests Routinebusiness.industryDisease progressionDiagnostic testGeneral MedicineMiddle AgedHuman senseClinical routineTest (assessment)SmellOtorhinolaryngologyReference valuesDisease ProgressionFeasibility StudiesFemalebusinessAmerican Journal of Rhinology & Allergy
researchProduct